Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation

Arnon Nagler; Vanderson Rocha; Myriam Labopin; Ali Unal; Tarek Ben Othman; Antonio Campos; Liisa Volin; Xavier Poire; Mahmoud Aljurf; Tamás Masszi; Gerard Socie; Henrik Sengelov; Mauricette Michallet; Jakob Passweg; Hendrik Veelken; Ibrahim Yakoub-Agha; Avichai Shimoni; Mohamad Mohty

doi:10.1200/JCO.2013.48.8114

Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation

Arnon Nagler, Vanderson Rocha, Myriam Labopin, Ali Unal, Tarek Ben Othman, Antonio Campos, Liisa Volin, Xavier Poire, Mahmoud Aljurf, Tamás Masszi, Gerard Socie, Henrik Sengelov, Mauricette Michallet, Jakob Passweg, Hendrik Veelken, Ibrahim Yakoub-Agha, Avichai Shimoni, Mohamad Mohty

147 Citationer (Scopus)

Abstract

Cyclophosphamide (Cy) combined with total-body irradiation (TBI) or with busulfan (Bu) are currently the most common myeloablative regimens used in allogeneic stem-cell transplantation (alloSCT) in adults with acute myelogenous leukemia (AML). Intravenous (IV) Bu has more predictable bioavailability and a safer toxicity profile than the oral formulation. Comparative studies of outcomes have been performed between oral Bu/Cy and Cy/TBI, but there have been no comparative trials in the era of IV Bu.

Originalsprog	Engelsk
Tidsskrift	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Vol/bind	31
Udgave nummer	28
Sider (fra-til)	3549-56
Antal sider	8
ISSN	0732-183X
DOI	https://doi.org/10.1200/JCO.2013.48.8114
Status	Udgivet - 1 okt. 2013

Adgang til dokumentet

10.1200/JCO.2013.48.8114

Andre filer og links

Link to publication in Scopus

Fingeraftryk

Dyk ned i forskningsemnerne om 'Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Nagler, A., Rocha, V., Labopin, M., Unal, A., Ben Othman, T., Campos, A., Volin, L., Poire, X., Aljurf, M., Masszi, T., Socie, G., Sengelov, H., Michallet, M., Passweg, J., Veelken, H., Yakoub-Agha, I., Shimoni, A., & Mohty, M. (2013). Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(28), 3549-56. https://doi.org/10.1200/JCO.2013.48.8114

Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation. / Nagler, Arnon; Rocha, Vanderson; Labopin, Myriam et al.
I: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Bind 31, Nr. 28, 01.10.2013, s. 3549-56.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Nagler, A, Rocha, V, Labopin, M, Unal, A, Ben Othman, T, Campos, A, Volin, L, Poire, X, Aljurf, M, Masszi, T, Socie, G, Sengelov, H, Michallet, M, Passweg, J, Veelken, H, Yakoub-Agha, I, Shimoni, A & Mohty, M 2013, 'Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, bind 31, nr. 28, s. 3549-56. https://doi.org/10.1200/JCO.2013.48.8114

Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 okt. 1;31(28):3549-56. doi: 10.1200/JCO.2013.48.8114

Nagler, Arnon ; Rocha, Vanderson ; Labopin, Myriam et al. / Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission : comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation. I: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 ; Bind 31, Nr. 28. s. 3549-56.

@article{42b028beaa0d4a4780f86d2b4a12febb,

title = "Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation",

abstract = "Cyclophosphamide (Cy) combined with total-body irradiation (TBI) or with busulfan (Bu) are currently the most common myeloablative regimens used in allogeneic stem-cell transplantation (alloSCT) in adults with acute myelogenous leukemia (AML). Intravenous (IV) Bu has more predictable bioavailability and a safer toxicity profile than the oral formulation. Comparative studies of outcomes have been performed between oral Bu/Cy and Cy/TBI, but there have been no comparative trials in the era of IV Bu.",

keywords = "Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Busulfan, Chemoradiotherapy, Cyclophosphamide, Female, Follow-Up Studies, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Injections, Intravenous, Leukemia, Myeloid, Acute, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Prognosis, Remission Induction, Retrospective Studies, Survival Rate, Transplantation Conditioning, Transplantation, Homologous, Whole-Body Irradiation, Young Adult",

author = "Arnon Nagler and Vanderson Rocha and Myriam Labopin and Ali Unal and \{Ben Othman\}, Tarek and Antonio Campos and Liisa Volin and Xavier Poire and Mahmoud Aljurf and Tam{\'a}s Masszi and Gerard Socie and Henrik Sengelov and Mauricette Michallet and Jakob Passweg and Hendrik Veelken and Ibrahim Yakoub-Agha and Avichai Shimoni and Mohamad Mohty",

year = "2013",

month = oct,

day = "1",

doi = "10.1200/JCO.2013.48.8114",

language = "English",

volume = "31",

pages = "3549--56",

journal = "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "28",

}

TY - JOUR

T1 - Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission

T2 - comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation

AU - Nagler, Arnon

AU - Rocha, Vanderson

AU - Labopin, Myriam

AU - Unal, Ali

AU - Ben Othman, Tarek

AU - Campos, Antonio

AU - Volin, Liisa

AU - Poire, Xavier

AU - Aljurf, Mahmoud

AU - Masszi, Tamás

AU - Socie, Gerard

AU - Sengelov, Henrik

AU - Michallet, Mauricette

AU - Passweg, Jakob

AU - Veelken, Hendrik

AU - Yakoub-Agha, Ibrahim

AU - Shimoni, Avichai

AU - Mohty, Mohamad

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Cyclophosphamide (Cy) combined with total-body irradiation (TBI) or with busulfan (Bu) are currently the most common myeloablative regimens used in allogeneic stem-cell transplantation (alloSCT) in adults with acute myelogenous leukemia (AML). Intravenous (IV) Bu has more predictable bioavailability and a safer toxicity profile than the oral formulation. Comparative studies of outcomes have been performed between oral Bu/Cy and Cy/TBI, but there have been no comparative trials in the era of IV Bu.

AB - Cyclophosphamide (Cy) combined with total-body irradiation (TBI) or with busulfan (Bu) are currently the most common myeloablative regimens used in allogeneic stem-cell transplantation (alloSCT) in adults with acute myelogenous leukemia (AML). Intravenous (IV) Bu has more predictable bioavailability and a safer toxicity profile than the oral formulation. Comparative studies of outcomes have been performed between oral Bu/Cy and Cy/TBI, but there have been no comparative trials in the era of IV Bu.

KW - Adolescent

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Busulfan

KW - Chemoradiotherapy

KW - Cyclophosphamide

KW - Female

KW - Follow-Up Studies

KW - Graft vs Host Disease

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Injections, Intravenous

KW - Leukemia, Myeloid, Acute

KW - Male

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Neoplasm Staging

KW - Prognosis

KW - Remission Induction

KW - Retrospective Studies

KW - Survival Rate

KW - Transplantation Conditioning

KW - Transplantation, Homologous

KW - Whole-Body Irradiation

KW - Young Adult

UR - https://www.scopus.com/pages/publications/84891601014

U2 - 10.1200/JCO.2013.48.8114

DO - 10.1200/JCO.2013.48.8114

M3 - Journal article

C2 - 23980086

SN - 0732-183X

VL - 31

SP - 3549

EP - 3556

JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

IS - 28

ER -